Vir Biotechnology Inc Forecast, price target & analysts
Vir Biotechnology Inc Target price 2025 - Analyst rating & recommendation
Vir Biotechnology Inc Classifications & Recommendation:
Vir Biotechnology Inc Price Target
| Target Price | $31.38 |
| Price | $9.57 |
| Potential |
227.85%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Vir Biotechnology Inc 2026 .
The average Vir Biotechnology Inc target price is $31.38.
This is
227.85%
register free of charge
$110.00
1,049.43%
register free of charge
$14.00
46.29%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Vir Biotechnology Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2026 of
227.85%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 86.18 | 68.66 |
| 94.67% | 20.33% | |
| EBITDA Margin | -744.43% | -863.53% |
| 1,517.52% | 16.00% | |
| Net Margin | -728.13% | -783.10% |
| 2,346.96% | 7.55% |
8 Analysts have issued a sales forecast Vir Biotechnology Inc 2024 . The average Vir Biotechnology Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2024. The average Vir Biotechnology Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Vir Biotechnology Inc Analysts have issued a net profit forecast 2024. The average Vir Biotechnology Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.59 | -3.93 |
| 219.84% | 14.38% | |
| P/E | negative | |
| EV/Sales | 6.22 |
6 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Vir Biotechnology Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Vir Biotechnology Inc...
Current Vir Biotechnology Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Jan 31 2025 |
| Leerink Partners | Outperform ➜ Outperform | Unchanged | Jan 13 2025 |
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Jan 10 2025 |
| Morgan Stanley | Equal-Weight ➜ Overweight | Upgrade | Jan 09 2025 |
| JP Morgan | Neutral ➜ Neutral | Unchanged | Jan 09 2025 |
| Needham | Buy ➜ Buy | Unchanged | Nov 20 2024 |
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Nov 20 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Jan 31 2025 |
|
Unchanged
Leerink Partners: Outperform ➜ Outperform
|
Jan 13 2025 |
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Jan 10 2025 |
|
Upgrade
Morgan Stanley: Equal-Weight ➜ Overweight
|
Jan 09 2025 |
|
Unchanged
JP Morgan: Neutral ➜ Neutral
|
Jan 09 2025 |
|
Unchanged
Needham: Buy ➜ Buy
|
Nov 20 2024 |
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Nov 20 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
